Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IDRA
  • CUSIP: N/A
  • Web:
  • Market Cap: $283.38 million
  • Outstanding Shares: 149,148,000
Average Prices:
  • 50 Day Moving Avg: $1.73
  • 200 Day Moving Avg: $1.85
  • 52 Week Range: $1.30 - $3.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.28 million
  • Price / Sales: 17.41
  • Book Value: $0.61 per share
  • Price / Book: 3.11
  • EBIDTA: ($40,350,000.00)
  • Net Margins: -249.48%
  • Return on Equity: -53.37%
  • Return on Assets: -48.00%
  • Current Ratio: 13.64%
  • Quick Ratio: 13.64%
  • Average Volume: 965,929 shs.
  • Beta: 2.19
  • Short Ratio: 11.71

Frequently Asked Questions for Idera Pharmaceuticals (NASDAQ:IDRA)

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.00. The business earned $0.38 million during the quarter, compared to the consensus estimate of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 53.37% and a negative net margin of 249.48%. View Idera Pharmaceuticals' Earnings History.

Where is Idera Pharmaceuticals' stock going? Where will Idera Pharmaceuticals' stock price be in 2017?

4 brokers have issued twelve-month price objectives for Idera Pharmaceuticals' shares. Their forecasts range from $2.10 to $8.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $5.28 in the next year. View Analyst Ratings for Idera Pharmaceuticals.

What are analysts saying about Idera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (7/6/2017)
  • 2. Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Independent Chairman of the Board
  • Vincent J. Milano, President, Chief Executive Officer, Director
  • Youssef El Zein, Independent Vice Chairman of the Board
  • Louis J. Arcudi III, Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
  • Robert Clayton Fletcher, Senior Vice President - Business Development and Strategic Planning
  • Joanna C. Horobin M.D., Senior Vice President, Chief Medical Officer
  • Robert A. Doody Jr., Vice President - Investor Relations and Corporate Communications
  • William S. Reardon CPA, Lead Independent Director
  • Maxine Gowen Ph.D., Director
  • Julian C. Baker, Independent Director

Who owns Idera Pharmaceuticals stock?

Idera Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Hollencrest Securities LLC (0.12%) and Leavell Investment Management Inc. (0.05%). Company insiders that own Idera Pharmaceuticals stock include Invest Corp Pillar, James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

How do I buy Idera Pharmaceuticals stock?

Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of Idera Pharmaceuticals stock can currently be purchased for approximately $1.90.

MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.28 (177.63% upside)

Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/24/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$5.00MediumView Rating Details
4/11/2017WedbushReiterated RatingOutperform$6.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$8.00HighView Rating Details
11/29/2016Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 -> $2.10N/AView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Earnings History by Quarter for Idera Pharmaceuticals (NASDAQ IDRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.10)($0.10)$0.20 million$0.38 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.11)$0.01$0.32 million$15.28 millionViewN/AView Earnings Details
10/28/2016Q3($0.11)($0.10)$0.30 million$0.32 millionViewN/AView Earnings Details
8/2/2016Q216($0.11)($0.11)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)$0.20 million$0.29 millionViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$0.03 million$0.19 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)$0.02 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)$0.01 millionViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)$0.03 millionViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)$0.04 millionViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)
2017 EPS Consensus Estimate: ($0.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.10)($0.10)($0.10)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Ownership Percentage: 30.29%
Institutional Ownership Percentage: 31.42%
Insider Trades by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Trades by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Invest Corp PillarDirectorSell450,815$2.26$1,018,841.90View SEC Filing  
4/25/2017Invest Corp PillarDirectorSell1,328,422$2.29$3,042,086.38View SEC Filing  
4/24/2017Invest Corp PillarDirectorSell437,829$2.29$1,002,628.41View SEC Filing  
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.12View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.00View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Idera Pharmaceuticals (NASDAQ:IDRA)
Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)
DateHeadline logoETFs with exposure to Idera Pharmaceuticals, Inc. : July 11, 2017 - July 11 at 11:40 PM logoIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Upgraded by Zacks Investment Research to "Hold" - July 9 at 2:56 PM logoTechnical Insights on Biotech Stocks -- Idera Pharma, Pieris Pharma, Peregrine Pharma, and Ritter Pharma - July 5 at 8:15 AM logoIdera Pharmaceuticals, Inc. (IDRA) Receives Consensus Rating of "Hold" from Analysts - June 28 at 12:05 AM logoIdera Pharma (IDRA) Granted FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma - June 23 at 6:10 PM logo3 Stocks to Watch on Friday: Bed Bath & Beyond Inc. (BBBY), Sonic Corporation (SONC) and Idera Pharmaceuticals Inc (IDRA) - June 23 at 8:34 AM logoIdera Pharma (IDRA) Granted FDA Orphan Drug Designation for ... - - June 23 at 1:21 AM logoIdera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma - June 22 at 8:17 PM logoIdera Pharmaceuticals, Inc. (IDRA) - June 10 at 4:15 AM logoIdera to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release) - June 5 at 10:56 PM logoIdera to Present at the Jefferies 2017 Healthcare Conference - Nasdaq - June 5 at 5:55 PM logoIdera to Present at the Jefferies 2017 Healthcare Conference - June 5 at 5:55 PM logoIdera Pharmaceuticals Inc (IDRA) Stock Rating Lowered by ValuEngine - June 4 at 11:14 AM logoIdera Pharmaceuticals Inc (IDRA) Receives Consensus Recommendation of "Hold" from Brokerages - June 2 at 4:04 PM logoETFs with exposure to Idera Pharmaceuticals, Inc. : June 1, 2017 - June 1 at 6:39 PM logoETFs with exposure to Idera Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 5:20 PM logoETFs with exposure to Idera Pharmaceuticals, Inc. : May 11, 2017 - May 11 at 6:27 PM logoIdera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 1:25 PM logoIdera Pharmaceuticals Inc (IDRA) Stock Rating Lowered by Zacks Investment Research - May 6 at 12:36 AM logoIdera Pharmaceuticals Inc (IDRA) Rating Lowered to Sell at Zacks Investment Research - May 6 at 12:33 AM logoIdera Pharmaceuticals (IDRA) Receiving Somewhat Favorable Media Coverage, Report Finds - May 5 at 11:22 PM logoHere's Why Idera Pharmaceuticals, Inc. Is Sinking Today - Motley Fool - May 5 at 10:52 PM logoHere's Why Idera Pharmaceuticals, Inc. Is Sinking Today - May 5 at 5:50 PM logoIdera Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IDRA) : May 5, 2017 - May 5 at 5:50 PM logoIdera Pharmaceuticals Inc (IDRA) Issues Earnings Results - May 5 at 4:40 PM logoIdera reports 1Q loss - May 4 at 6:57 PM logoIdera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 4 at 6:02 PM logoIdera Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IDRA-US : May 4, 2017 - May 4 at 11:25 AM logoIdera Pharmaceuticals Inc (IDRA) Director Sells $1,018,841.90 in Stock - May 4 at 1:09 AM logoSomewhat Positive Media Coverage Somewhat Likely to Affect Idera Pharmaceuticals (IDRA) Share Price - April 28 at 5:57 PM logoInvest Corp Pillar Sells 437,829 Shares of Idera Pharmaceuticals Inc (IDRA) Stock - April 26 at 10:54 PM logoInsider Selling: Idera Pharmaceuticals Inc (IDRA) Director Sells 1,328,422 Shares of Stock - April 26 at 8:16 PM logoBaird Starts Idera Pharmaceuticals (IDRA) at Outperform - - April 26 at 7:29 PM logoWith More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform - Benzinga - April 26 at 7:29 PM logoIdera Pharmaceuticals Inc (IDRA) Coverage Initiated at Robert W. Baird - April 24 at 9:46 PM logoIdera Pharmaceuticals (IDRA) Receives Daily Coverage Optimism Rating of 0.14 - April 24 at 7:04 PM logoToday's Research Reports on Biotech Stocks to Watch: Idera ... - Yahoo Finance - April 22 at 8:12 AM logoFavorable Media Coverage Extremely Likely to Affect Idera Pharmaceuticals (IDRA) Share Price - April 21 at 8:07 PM logoToday's Research Reports on Biotech Stocks to Watch: Idera Pharmaceuticals and ZIOPHARM Oncology - April 21 at 10:44 AM logoExclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate - April 20 at 10:58 PM logoIdera Pharmaceuticals Announces Organizational Update - GlobeNewswire (press release) - April 19 at 5:43 PM logoIdera Pharmaceuticals Announces Organizational Update - April 18 at 5:22 PM logoIdera Pharmaceuticals (IDRA) Getting Favorable News Coverage, Analysis Finds - April 18 at 1:58 PM logoIdera Pharmaceuticals Inc (IDRA) Receives "Outperform" Rating from Wedbush - April 14 at 5:27 PM logoIdera Pharmaceuticals Inc (IDRA) Short Interest Update - April 13 at 7:30 AM logoIdera Pharma (IDRA) Advances Intratumoral IMO-2125 in Combination with Ipilimumab for Unmet Need in Anti-PD-1 ... - - April 12 at 5:58 PM logoIdera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma - April 11 at 11:57 AM logoIdera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting - April 7 at 10:23 AM logo Idera Pharmaceuticals Inc (IDRA) Given Average Rating of "" by Brokerages - March 30 at 12:01 PM logoIdera Pharmaceuticals and XOMA Find Paths to Financial Growth - March 23 at 6:24 PM



Idera Pharmaceuticals (IDRA) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff